Best Life Sciences Companies in San Antonio, United States

Developer of drug-delivery solution for the treatment of pediatric wart treatment. The company's proprietary product WartPatch is a drug delivery platform for kids for the treatment of dermatological problems.

Funding rounds

• Oct 2025Series C$150M
• Dec 2024Series B$75M
• May 2023Series B$15M
• Sep 2021Series A$22.2M

Founders & team

Kyle RyderFounder

Investors

Prospect Hill Growth Partners, Connecticut Innovations, Suvretta Capital Management, Longitude Capital, Citadel, Osage University Partners

Tech stack

AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch

Innovating medical technologies, from development to commercialization, improving clinical outcomes. They fuse business with science, linking innovations with consumers. They focus on achieving superior clinical outcomes and producing truly innovative medical products. They form collaborative partnerships with scientists, supporting their research and bringing resulting products to the marketplace. Their model uses non-dilutive government funding to demonstrate product safety and technology feasibility. They are committed to combining rigorous processes with an accomplished staff, accelerating technology transfer and commercialization. They offer formulation development, regulatory expertise, and manufacturing capabilities. They develop products like mouth rinse, software platform, and skincare.

Developer of IVD and targets cancer cells for therapeutics. The company design a platform for the detection and treatment of many cancers. The first product of the company CyPath is a bio label with a high affinity for cancer cells. This label technology allows cancer cells to fluoresce, leading to detection.

Cell culture technology company advancing regenerative medicine and drug discovery. They specialize in cell-derived matrices that mimic the natural cellular environment, fostering more biologically relevant cell behavior. Their CELLvo™ technology supports stem cell expansion, cardiomyocyte maturation, and improved cell differentiation. They offer a range of cell culture products, including matrices and cells, designed to enhance research outcomes. They also provide custom pre-coating services for cell culture surfaces. Their technology facilitates predictive, cell-based assays, cardiotoxicity screening, and regenerative medicine research. They focus on innovation and collaboration to provide researchers with advanced tools for cell culture and analysis.

Funding rounds

• Feb 2025Grant (prize money)$300K
• Mar 2023Grant (prize money)$300K
• Jun 2019Series A$1.4M
• Sep 2018Grant (prize money)$143K

Founders & team

Robert HutchensPresident & CEO; Member of the Board of Directors

Investors

Targeted Technology, Metric Medical Devices, HHS, Fountainhead Investment Partners, JLABS

Developer of diagnostic test kit for endometriosis. The company has developed MetriDx a novel, non-surgical method for the early diagnosis and staging of endometriosis. The endometrium is collected using a uterine brush biopsy during an in-office procedure, thereby eliminating the need for surgery.

Funding rounds

• Sep 2025Seed$250K
• Apr 2025Seed$796.3K
• May 2023Seed$260K
• Aug 2022Seed$1.9M

Founders & team

Bruce NicholsonCo-FounderNameer KirmaCo-FounderPaul CastellaCo-Founder & Executive Chairman

Investors

Coyote Ventures, Althea Group, The University of Texas at Austin, Stella, Birmingham Angels, VentureDNA

Developer of a device for organ preservation. In organ transplant therapy most organs are rejected because they can’t reach patients in time. Its product is the VP.S ENCORE device is designed to extend the viability of organs outside the body beyond the current standard of care (SOC) which uses ice-cooling.

Revolutionizing hemorrhage control with innovative medical devices for saving lives. This company is dedicated to developing and providing solutions for temporary management of severe bleeding. Their patented, FDA-cleared iTClamp is engineered for rapid application and effective hemorrhage containment in critical areas. It equalizes pressure to prevent additional blood loss, offering a stabilized clot until surgical repair. The iTClamp is a TCCC-recommended solution for pre-hospital, hospital, and tactical environments, addressing difficult-to-control bleeds. It offers benefits such as hands-free operation, minimal training requirements, and reduced patient pain. The company focuses on saving lives by providing a fast, versatile, and proven tool for hemorrhage control, supported by clinical information and worldwide support.

Funding rounds

• Dec 2024Series A$100K
• Aug 2023Series A$255K
• Feb 2015Unattributed$62K
• Jan 2014Series A$8.4M

Founders & team

Joe BrennanCEO

Investors

Valhalla Angels, City of San Antonio, Targeted Technology

Tech stack

BootstrapCloudflareCore-JsElementorGoogle WorkspaceGtranslate

Spinal medical device company specializing in nucleus replacement technology for back pain. They focus on the design, development, and manufacturing of spinal medical devices. Their primary offering is a lumbar intervertebral disc nucleus replacement designed to alleviate chronic low back pain associated with degenerative disc disease. The technology aims to recreate physiological motion and redistribute weight-bearing forces within the disc. They are committed to meeting the expectations of patients, customers, and regulatory agencies while maintaining a robust quality management system. Their focus is on providing innovative solutions for spinal stabilization through advanced medical device engineering.

Funding rounds

• Jan 2025Series B$16.9M
• Jul 2018Series A$11.2M

Founders & team

Mark NovotnyCEO & President

Investors

Running M Capital

AI based platform to streamline the marketing compliance process within the life sciences industry. It provides solutions to enhance content creation and compliance reviews in the pharmaceutical marketing sector. It provides specific and actionable recommendations tailored to a companys data, helping teams identify drug related content issues early in the process.

Funding rounds

• Nov 2024Seed$4M

Founders & team

Jaya PlmanabhanChief Data Officer & Co-FounderFerry TamtoroCEO & Co-Founder

Investors

Live Oak Ventures, Lilly, Tau Ventures, Arkin Holdings, Arkin

Tech stack

CloudflareCloudflare Bot ManagementCore-JsFramer SitesGoogle AnalyticsGoogle Font Api

EO2Concepts develops and commercializes electrochemical low-dose tissue oxygenation and wound monitoring systems for the treatment of chronic wounds to promote tissue viability. The device, TransCu O2, is a portable oxygen concentrator for wound care that feeds a continuous stream of pure oxygen directly to the wound 24/7 to aid in the wound healing process. It utilizes enhanced fuel cell technology to electrochemically generate pure oxygen. FDA cleared Class II medical device.

Provider of a device for repositioning patients in hospitals. The Pronova-O2 automated prone therapy system is used to prevent pressure injuries, helps in the management of patients with pulmonary distress and complications in patient immobility.

Funding rounds

• Jul 2023Series A$4.7M
• Feb 2022Seed$3.8M
• Sep 2021Seed$2.4M

Founders & team

Tara PsencikCEO

Tech stack

BluehostCart FunctionalityCloudflareCloudflare Bot ManagementCloudwaysCore-Js

Xenex provides disinfection robots for multiple healthcare purposes. It offers hospital sterilization robots that use strong, ultraviolet lights (termed patented Xenon Pulse or UV technology) to kill infection-causing microorganisms. Their patented room disinfection system reduces the bacterial load that is often associated with an increased risk for healthcare-associated infections (HAIs).